You have access
Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
Sébastien Anguille, Evelien L. Smits, Christian Bryant, Heleen H. Van Acker, Herman Goossens, Eva Lion, Phillip D. Fromm, Derek N. Hart, Viggo F. Van Tendeloo and Zwi N. Berneman
Michael G. Rosenblum, ASSOCIATE EDITOR, Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute, Laboratory of Experimental Hematology, Tumor Immunology Group (S.A., H.H.V.A., H.G., E.L., V.F.V.T., Z.N.B.), and Faculty of Medicine and Health Sciences, Center for Oncological Research (E.L.S.), University of Antwerp, Antwerp, Belgium; Center for Cell Therapy & Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium (S.A., E.L.S., Z.N.B.); and ANZAC Research Institute, Dendritic Cell Biology and Therapeutics Group, University of Sydney, Sydney, New South Wales, Australia (C.B., P.D.F., D.N.H.)
Pharmacological Reviews October 2015, 67 (4) 731-753; DOI: https://doi.org/10.1124/pr.114.009456